Published in Women's Health Weekly, May 13th, 2004
Conceptus expects that this change will result in a significant decrease in manufacturing costs, which would enable Conceptus to become profitable in 2005.
"This approval caps the year-long project to bring the Venusa facility on line to manufacture Essure," said William Dippel, VP of manufacturing and R&D for Conceptus. "We are already shifting production to this facility, and should see an immediate savings in manufacturing costs."
...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.